These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 20112379)

  • 1. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis.
    Farina G; Lafyatis D; Lemaire R; Lafyatis R
    Arthritis Rheum; 2010 Feb; 62(2):580-8. PubMed ID: 20112379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta.
    Farina G; Lemaire R; Pancari P; Bayle J; Widom RL; Lafyatis R
    Ann Rheum Dis; 2009 Mar; 68(3):435-41. PubMed ID: 18408251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis.
    Rice LM; Ziemek J; Stratton EA; McLaughlin SR; Padilla CM; Mathes AL; Christmann RB; Stifano G; Browning JL; Whitfield ML; Spiera RF; Gordon JK; Simms RW; Zhang Y; Lafyatis R
    Arthritis Rheumatol; 2015 Nov; 67(11):3004-15. PubMed ID: 26240058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.
    Rice LM; Padilla CM; McLaughlin SR; Mathes A; Ziemek J; Goummih S; Nakerakanti S; York M; Farina G; Whitfield ML; Spiera RF; Christmann RB; Gordon JK; Weinberg J; Simms RW; Lafyatis R
    J Clin Invest; 2015 Jul; 125(7):2795-807. PubMed ID: 26098215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker.
    Hesselstrand R; Kassner A; Heinegård D; Saxne T
    Ann Rheum Dis; 2008 Sep; 67(9):1242-8. PubMed ID: 18065498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput quantitative histology in systemic sclerosis skin disease using computer vision.
    Correia C; Mawe S; Lofgren S; Marangoni RG; Lee J; Saber R; Aren K; Cheng M; Teaw S; Hoffmann A; Goldberg I; Cowper SE; Khatri P; Hinchcliff M; Mahoney JM
    Arthritis Res Ther; 2020 Mar; 22(1):48. PubMed ID: 32171325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cartilage oligomeric matrix protein is overexpressed by scleroderma dermal fibroblasts.
    Farina G; Lemaire R; Korn JH; Widom RL
    Matrix Biol; 2006 May; 25(4):213-22. PubMed ID: 16520029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma.
    Low AHL; Ng SA; Berrocal V; Brennan B; Chan G; Ng SC; Khanna D
    Int J Rheum Dis; 2019 Jun; 22(6):1036-1040. PubMed ID: 30838791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cartilage Oligomeric Matrix Protein (COMP) in systemic sclerosis (SSc): role in disease severity and subclinical rheumatoid arthritis overlap.
    Gheita TA; Hussein H
    Joint Bone Spine; 2012 Jan; 79(1):51-6. PubMed ID: 21497537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis.
    Christmann RB; Sampaio-Barros P; Stifano G; Borges CL; de Carvalho CR; Kairalla R; Parra ER; Spira A; Simms R; Capellozzi VL; Lafyatis R
    Arthritis Rheumatol; 2014 Mar; 66(3):714-25. PubMed ID: 24574232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis.
    Hinchcliff M; Huang CC; Wood TA; Matthew Mahoney J; Martyanov V; Bhattacharyya S; Tamaki Z; Lee J; Carns M; Podlusky S; Sirajuddin A; Shah SJ; Chang RW; Lafyatis R; Varga J; Whitfield ML
    J Invest Dermatol; 2013 Aug; 133(8):1979-89. PubMed ID: 23677167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time.
    Skaug B; Lyons MA; Swindell WR; Salazar GA; Wu M; Tran TM; Charles J; Vershel CP; Mayes MD; Assassi S
    Ann Rheum Dis; 2022 Apr; 81(4):516-523. PubMed ID: 34937693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-like receptor 9 in systemic sclerosis patients: relation to modified Rodnan skin score, disease severity, and functional status.
    Gheita TA; Sayed S; Azkalany GS; Abaza N; Hammam N; Eissa AH
    Clin Rheumatol; 2018 Mar; 37(3):757-763. PubMed ID: 29076114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of EUSTAR standardized training on accuracy of modified Rodnan skin score in patients with systemic sclerosis.
    Park JW; Ahn GY; Kim JW; Park ES; Kang JH; Chang SH; Choi IA; Yoo SJ; Park JK; Shin K; Park YB; Jun JB; Czirják L; Allanore Y; Matucci-Cerinic M; Lee EB
    Int J Rheum Dis; 2019 Jan; 22(1):96-102. PubMed ID: 30398033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Modified Hand Mobility in Scleroderma Test and Skin Involvement - A Followup Study.
    Sandqvist G; Wuttge DM; Hesselstrand R
    J Rheumatol; 2016 Jul; 43(7):1356-62. PubMed ID: 27134250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
    Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
    Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin fibrosis correlates with circulating thyrotropin levels in systemic sclerosis: translational association with Hashimoto's thyroiditis.
    Bagnato GL; Roberts WN; Fiorenza A; Arcuri C; Certo R; Trimarchi F; Ruggeri RM; Bagnato GF
    Endocrine; 2016 Feb; 51(2):291-7. PubMed ID: 25994300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations between nailfold microvascular damage and skin involvement in systemic sclerosis patients.
    Ruaro B; Pizzorni C; Paolino S; Smith V; Ghio M; Casabella A; Alessandri E; Patané M; Sulli A; Cutolo M
    Microvasc Res; 2019 Sep; 125():103874. PubMed ID: 30974112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
    Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
    Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial.
    Merkel PA; Silliman NP; Denton CP; Furst DE; Khanna D; Emery P; Hsu VM; Streisand JB; Polisson RP; Akesson A; Coppock J; van den Hoogen F; Herrick A; Mayes MD; Veale D; Seibold JR; Black CM; Korn JH; ;
    Arthritis Rheum; 2008 May; 59(5):699-705. PubMed ID: 18438905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.